Amicus Therapeutics (NASDAQ:FOLD) Receives Media Impact Rating of 0.20
Press coverage about Amicus Therapeutics (NASDAQ:FOLD) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amicus Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.5218855246697 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Down 4.4% in July (americanbankingnews.com)
- Uptrend Call Working As Amicus Therapeut Stock Rises 97.8% (FOLD) (mysmartrend.com)
- Amicus Therapeutics Sees Unusually Large Options Volume (NASDAQ:FOLD) (americanbankingnews.com)
- Amicus Therapeutics, Inc. (FOLD) Earns Overweight Rating from J P Morgan Chase & Co (americanbankingnews.com)
- Comparing Price Charts: Bristow Group Inc. (BRS), Amicus Therapeutics, Inc. (FOLD) – StockNewsMagazine (stocknewsmagazine.com)
Amicus Therapeutics (NASDAQ:FOLD) traded up 2.64% on Friday, reaching $12.05. 3,625,435 shares of the company’s stock traded hands. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $14.05. The stock’s market cap is $1.98 billion. The stock has a 50 day moving average price of $12.20 and a 200 day moving average price of $8.49.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter in the prior year, the company earned ($0.40) earnings per share. Analysts forecast that Amicus Therapeutics will post ($1.41) EPS for the current year.
A number of research analysts recently weighed in on the stock. Robert W. Baird restated an “outperform” rating and set a $12.00 price objective (up previously from $10.00) on shares of Amicus Therapeutics in a research report on Wednesday, May 17th. Chardan Capital increased their price objective on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a research report on Thursday. BidaskClub downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 12th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Amicus Therapeutics presently has an average rating of “Buy” and an average price target of $14.58.
In other news, insider Jay Barth sold 30,000 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $10.00, for a total transaction of $300,000.00. Following the sale, the insider now owns 64,184 shares of the company’s stock, valued at $641,840. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Hung Do sold 29,914 shares of the stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the sale, the insider now directly owns 474,438 shares in the company, valued at approximately $3,795,504. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by corporate insiders.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.